Iovance Biotherapeutics (IOVA) News Today

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) saw its shares decline amid mounting legal notices and the resignation of its CFO, despite neutral commentary on its clinical pipeline.

• Neutral Sentiment: Analysis of ASCO trial results, competitor data and strategic outlook offers updated insight into Iovance’s pipeline progress and market positioning. Iovance Biotherapeutics: ASCO Update, Competitor Data And The Road Ahead
• Negative Sentiment: The Gross Law Firm issued a notice to IOVA shareholders about a pending federal securities class action lawsuit and reminded them of the July 14, 2025 lead plaintiff deadline. The Gross Law Firm Reminds Iovance Biotherapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 14, 2025 - IOVA
• Negative Sentiment: Faruqi & Faruqi announced an investigation into potential securities claims against Iovance and highlighted the July 14, 2025 deadline for lead plaintiff applications. SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
• Negative Sentiment: Iovance’s CFO resigned, citing launch setbacks for its lead therapy and mounting legal pressures from securities lawsuits. Iovance's (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure– Hagens Berman
• Negative Sentiment: The Gross Law Firm invited investors who lost money on IOVA shares to join its securities class action seeking recovery by the July 14 deadline. Lost Money on Iovance Biotherapeutics, Inc. (IOVA)? Join Class Action Suit Seeking Recovery – Contact The Gross Law Firm
• Negative Sentiment: Levi & Korsinsky notified investors of a class action lawsuit against Iovance and urged shareholders to submit lead plaintiff applications by July 14. Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - IOVA
• Negative Sentiment: Pomerantz LLP reminded investors of a recently filed securities class action against Iovance and urged those with losses to contact counsel before the July 14 deadline. INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA
• Negative Sentiment: The DJS Law Group notified Iovance shareholders of their rights to lead the securities class action, with the July 14 deadline approaching. IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV
• Negative Sentiment: The Schall Law Firm alerted investors to a securities fraud class action against Iovance, emphasizing the opportunity to serve as lead plaintiff by July 14. IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
• Negative Sentiment: BFA Law notified IOVA investors of a securities fraud class action filed against the company and reminded them of the July 14 deadline. IOVA CLASS ACTION: A Class Action was filed against Iovance Biotherapeutics for Securities Fraud -- Contact BFA Law by July 14 Legal Deadline (NASDAQ:IOVA)